Loading...
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal 7% 5-year survival rate and is projected to become the second leading cause of cancer-related deaths by 2020. KRAS is mutated in 95% of PDACs and is a well-validated driver of PDAC growth and maintenance. However, d...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4846854/ https://ncbi.nlm.nih.gov/pubmed/27096871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers8040045 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|